U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28N2O5
Molecular Weight 388.4574
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMIPRILAT

SMILES

[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O

InChI

InChIKey=KEDYTOTWMPBSLG-HILJTLORSA-N
InChI=1S/C21H28N2O5/c1-13(22-16(20(25)26)11-10-14-6-3-2-4-7-14)19(24)23-17-9-5-8-15(17)12-18(23)21(27)28/h2-4,6-7,13,15-18,22H,5,8-12H2,1H3,(H,25,26)(H,27,28)/t13-,15-,16-,17-,18-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H28N2O5
Molecular Weight 388.4574
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16398929

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

CNS Activity

Originator

Approval Year

1991
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Preventing
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Primary
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
43.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
24 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
414 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Other AEs: Headache, Cough...
Other AEs:
Headache (13%)
Cough (33%)
Dizziness (13%)
Asthenia (19%)
Cramps (4%)
Diarrhea (4%)
Nausea (8%)
Palpitations (1%)
Dyspnea (1%)
Tinnitus (1%)
Malaise (3%)
Pruritus (1%)
Dry mouth (1%)
Polyuria (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Other AEs: Dizziness, Vertigo...
Other AEs:
Dizziness (6%)
Vertigo (6%)
Asthenia (4%)
Nausea (3%)
Headache (2%)
Abdominal pain (1%)
Gastrointestinal disorder (1%)
Rash (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dyspnea 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Palpitations 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Pruritus 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Tinnitus 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dizziness 13%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Headache 13%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Asthenia 19%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Malaise 3%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Polyuria 3%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cough 33%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cramps 4%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Diarrhea 4%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Nausea 8%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Abdominal pain 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Cough increased 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Gastrointestinal disorder 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Rash 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Headache 2%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Nausea 3%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Asthenia 4%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Dizziness 6%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Vertigo 6%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CES1
22

CES2
28
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
PEPT1
22
 yes
PEPT2
12
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
28
 no
CES1
22
 yes
PubMed

PubMed

TitleDatePubMed
ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function.
1999 Nov
Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.
1999 Oct
Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts.
2000 Feb
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
2000 Mar 15
Intrarenal renin-angiotensin system contributes to tubular acidification adaptation following uninephrectomy.
2001
Recent clinical trial highlights in hypertension.
2001 Apr
The kidney in cardiovascular disease.
2001 Apr 17
Study at up to 700 sites will build on landmark HOPE trial.
2001 Apr-May
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].
2001 Aug
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.
2001 Aug
[Diabetic nephropathy. Smoking also damages the kidney].
2001 Aug 23
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.
2001 Dec
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
2001 Feb 20
Pharmacoeconomic impact of HOPE.
2001 Jan
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
2001 Jul
Right atrial function in hypertensive patients: effects of antihypertensive therapy.
2001 Jul
Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation.
2001 Jul
Bradykinin metabolism in the isolated perfused rabbit heart.
2001 Jul
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
2001 Jul-Aug
The African American Study of Kidney Disease and Hypertension (AASK): new findings.
2001 Jul-Aug
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.
2001 Jun 12
[Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study].
2001 Jun 15
Management of asymptomatic left ventricular dysfunction.
2001 Mar
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
2001 Mar
Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs.
2001 Mar
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
2001 Mar-Apr
Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
2001 May
Endothelial nitric oxide synthase plays an essential role in regulation of renal oxygen consumption by NO.
2001 May
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.
2001 Nov
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
2001 Oct 2
[Atherosclerosis. High ACE activity in plaque: risk of rupture!].
2001 Oct 25
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
2001 Sep
[Ramipril can do more. Halting progression of atherosclerosis].
2001 Sep 6
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].
2001 Sep 6
Patents

Patents

06407262
2
20010002262
19
JP1066130A
10
JP2001501189A
7
JP2001508027A
37
JP2002535367A
24
JP2002536332A
38
JP2002538172A
25
JP2002541106A
98
JP2002541233A
400
JP2003501461A
2
JP2003503381A
35
JP2003507418A
31
JP2003508349A
45
JP2003515526A
462
JP2004531567A
7
JP2005500299A
34
JP2005527208A
2
JP2005527462A
21
JP2007514770A
75
JP2007518794A
2
JP2007520453A
33
JP2007524644A
48
JP2007525670A
148
JP2008167697A
2
JP2011506455A
51
JP2011510003A
48
JP2011510067A
57
JP2011524416A
138
JP2011528275A
455
JP2012500806A
10
JP2013544275A
6
JP4139440B2
7
JP4606172B2
28
JP4687863B2
2
JP4705912B2
47
JP4729259B2
38
JP4733348B2
2
JP4746258B2
2
JP4800961B2
2
JPH00219326A
2
JPH01165596A
2
JPH02121922A
13
JPH0219326A
2
JPH04179441A
2
JPH04308533A
5
JPS6466130A
5

Sample Use Guides

In Vivo Use Guide
Hypertension: The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. Adjust dose according to blood pressure response. The usual maintenance dosage range is 2.5 mg to 20 mg per day administered as a single dose or in two. Myocardial Infarction, Stroke, and Death from Cardiovascular Causes: Initiate dosing at 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, and then increase as tolerated, to a maintenance dose of 10 mg once daily. equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. Heart Failure Post-Myocardial Infarction: the recommended starting dose is 2.5 mg twice daily (5 mg per day). A patient who becomes hypotensive at this dose may be switched to 1.25 mg twice daily. After one week at the starting dose, increase dose (if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The effect of ramipril on DNA synthesis, cell proliferation and PDGF A and B chain gene expression in fetal calf serum (FCS)-activated cultured human glomerular mesangial cells was investigated. Ramipril significantly reduced FCS-induced PDGF A and B chain gene expression, completely abolished the PDGF A and B chain gene expression induced by phorbol 12-myristate 13-acetate, a specific protein kinase C activator, suggesting a site of action downstream of this enzyme in the mitogenic signal transduction pathway.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:23 GMT 2023
Edited
by admin
on Fri Dec 15 16:35:23 GMT 2023
Record UNII
6N5U4QFC3G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RAMIPRILAT
INN  
INN  
Official Name English
RAMIPRIL IMPURITY E [EP IMPURITY]
Common Name English
RAMIPRIL DIACID
Common Name English
ramiprilat [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
EU-Orphan Drug EU/3/13/1117
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
NCI_THESAURUS C247
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
Code System Code Type Description
PUBCHEM
5464096
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
IUPHAR
6344
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
DRUG BANK
DB14208
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
INN
5713
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
MESH
C052549
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
DAILYMED
6N5U4QFC3G
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
CAS
87269-97-4
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
RXCUI
1546377
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1201365
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
EVMPD
SUB10249MIG
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
NCI_THESAURUS
C72911
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
FDA UNII
6N5U4QFC3G
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
CHEBI
77363
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID401016165
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
SMS_ID
100000080313
Created by admin on Fri Dec 15 16:35:23 GMT 2023 , Edited by admin on Fri Dec 15 16:35:23 GMT 2023
PRIMARY
Related Record Type Details
Structure of RAMIPRIL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of RAMIPRIL
PARENT -> IMPURITY
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of RAMIPRILAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966